{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:13:00Z","timestamp":1791231180080,"version":"4.1.0"},"reference-count":83,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition characterized by the presence of low levels of a monoclonal protein in the serum and a low percentage of clonal plasma cells in the bone marrow. MGUS may progress to multiple myeloma or other plasma cell disorders at a rate of 1% annually. However, MGUS may also have adverse effects on the cardiovascular system independent of its malignant potential. Emerging data have shown that MGUS is associated with cardiovascular disease. The mechanisms underlying this association are not fully understood but may involve genetic abnormalities, vascular calcification, cryoglobulinemia, cold agglutinin disease, autoantibodies and the direct or indirect effects of the monoclonal protein on the vascular endothelium. Herein, we review current evidence in this field and we suggest that patients with MGUS may benefit from regular cardiovascular risk assessment to prevent severe cardiovascular complications, in parallel with close hematological follow-up to monitor potential disease progression.<\/jats:p>","DOI":"10.3390\/jcdd10120484","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T03:40:58Z","timestamp":1701661258000},"page":"484","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Monoclonal Gammopathy of Undetermined Cardiovascular Significance; Current Evidence and Novel Insights"],"prefix":"10.3390","volume":"10","author":[{"given":"Anastasios","family":"Tentolouris","sequence":"first","affiliation":[{"name":"First Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Andreadou","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, 15771 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: A novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3324\/haematol.2022.280953","article-title":"IgM monoclonal gammopathies of clinical significance: Diagnosis and management","volume":"107","author":"Khwaja","year":"2022","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/bloodadvances.2019031914","article-title":"Pathophysiology and management of monoclonal gammopathy of renal significance","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: A consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-019-0183-y","article-title":"Management of cardiovascular risk in patients with multiple myeloma","volume":"9","author":"Plummer","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gkalea, V., Fotiou, D., Dimopoulos, M.A., and Kastritis, E. (2023). Monoclonal Gammopathy of Thrombotic Significance. Cancers, 15.","DOI":"10.3390\/cancers15020480"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jaccao.2022.05.009","article-title":"Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study","volume":"4","author":"Schwartz","year":"2022","journal-title":"JACC CardioOncol"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaccao.2022.07.002","article-title":"Cardiovascular Associations with Monoclonal Gammopathy of Undetermined Significance: Real or Coincidental?","volume":"4","author":"Kapoor","year":"2022","journal-title":"JACC CardioOncol"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_13","unstructured":"International Diabetes Federation (2023, July 01). IDF Diabetes Atlas 10th Edition. Available online: https:\/\/diabetesatlas.org."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"18449","DOI":"10.1038\/s41598-021-97664-y","article-title":"A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea","volume":"11","author":"Kang","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hamadi, R., Alameddine, Z., Asmar, S., Sakr, F., Aridi, H., Dimachkie, R., and Skouri, H. (2023). Outcomes of Patients with Monoclonal Gammopathy of Undetermined Significance with and without Atrial Fibrillation: A Retrospective Cohort Analysis of the Nationwide Inpatient Sample Database. J. Clin. Med., 12.","DOI":"10.3390\/jcm12134436"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e3535","DOI":"10.1002\/dmrr.3535","article-title":"Diabetes mellitus and multiple myeloma; common features of two distinct entities","volume":"38","author":"Tentolouris","year":"2022","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Shah, U.A., Moshier, E.L., Derkach, A., Huang, Y., Mailankody, S., Tan, C.R., Maclachlan, K.H., Hultcrantz, M., Korde, N., and Hassoun, H. (Blood Adv., 2023). Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups, Blood Adv., Online ahead of print.","DOI":"10.1182\/bloodadvances.2023010815"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00277-021-04400-7","article-title":"Risk factors for monoclonal gammopathy of undetermined significance: A systematic review","volume":"100","author":"Ulbricht","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2021.278772","article-title":"Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls","volume":"107","author":"Shah","year":"2022","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.24355","article-title":"Reappraisal of risk factors for monoclonal gammopathy of undetermined significance","volume":"91","author":"Boursi","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","article-title":"Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women","volume":"116","author":"Landgren","year":"2010","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Grant, B., Ratnayake, G., Williams, C.L., Long, A., Halsall, D.J., Semple, R.K., Cavenagh, J.D., Drake, W.M., and Church, D.S. (2023). Resolution of dysglycaemia after treatment of monoclonal gammopathy of endocrine significance. Eur. J. Endocrinol., lvad138.","DOI":"10.1093\/ejendo\/lvad138"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2014.34","article-title":"Racial disparities in the prevalence of monoclonal gammopathies: A population-based study of 12,482 persons from the National Health and Nutritional Examination Survey","volume":"28","author":"Landgren","year":"2014","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.clml.2021.01.008","article-title":"Overweight\/Obesity and Monoclonal Gammopathy of Undetermined Significance","volume":"21","author":"Georgakopoulou","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/bloodadvances.2017007609","article-title":"Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: A population-based study","volume":"1","author":"Thordardottir","year":"2017","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.semcancer.2023.04.003","article-title":"Obesity and multiple myeloma: Emerging mechanisms and perspectives","volume":"92","author":"Tentolouris","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1096-8652(199607)52:3<217::AID-AJH15>3.0.CO;2-C","article-title":"Risk of monoclonal gammopathy of undetermined significance: A case-referent study","volume":"52","author":"Pasqualetti","year":"1996","journal-title":"Am. J. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1365-2141.1997.942910.x","article-title":"Tobacco smoking and risk of haematological malignancies in adults: A case-control study","volume":"97","author":"Pasqualetti","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_30","unstructured":"(2023, July 08). National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention, Available online: https:\/\/www.cdc.gov\/bloodpressure\/facts.htm#:~:text=Nearly%20half%20of%20adults%20haveatmfhtAia.CDCHypertension."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/ijc.34476","article-title":"Multimorbidity in patients with monoclonal gammopathy of undetermined significance","volume":"152","author":"Epstein","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","article-title":"Global epidemiology of dyslipidaemias","volume":"18","author":"Pirillo","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: Recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/ajh.26566","article-title":"Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors","volume":"97","author":"Gozzetti","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","article-title":"2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials","volume":"137","author":"Hicks","year":"2018","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dci17-0057","article-title":"Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go from Here? Reflections from a Diabetes Care Editors\u2019 Expert Forum","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: A population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","article-title":"Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: A multicentre cohort study","volume":"9","author":"Lee","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3324\/haematol.2009.010066","article-title":"Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: A population-based study","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"859","DOI":"10.4065\/79.7.859","article-title":"Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: The original Mayo Clinic series 25 years later","volume":"79","author":"Kyle","year":"2004","journal-title":"Mayo Clin. Proc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1365-2141.2001.02533.x","article-title":"Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance","volume":"112","author":"Gregersen","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000203676","article-title":"The natural history of monoclonal gammopathy of undetermined significance. A 5- to 20-year follow-up of 263 cases","volume":"97","author":"Pasqualetti","year":"1997","journal-title":"Acta Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s12265-019-09950-w","article-title":"MGUS Predicts Worse Prognosis in Patients with Coronary Artery Disease","volume":"13","author":"Xu","year":"2020","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.seminoncol.2022.11.001","article-title":"Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias","volume":"49","author":"Testa","year":"2022","journal-title":"Semin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1182\/blood-2021-147890","article-title":"MGUS and Chip: Two Faces, but Not of the Same Medal","volume":"138","author":"Lionetti","year":"2021","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/eurheartj\/ehu163","article-title":"Medial vascular calcification revisited: Review and perspectives","volume":"35","author":"Lanzer","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lee, S.J., Lee, I.K., and Jeon, J.H. (2020). Vascular Calcification-New Insights Into Its Mechanism. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082685"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1007\/s00125-009-1521-6","article-title":"Medial arterial calcification in diabetes and its relationship to neuropathy","volume":"52","author":"Jeffcoate","year":"2009","journal-title":"Diabetologia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/bjh.17256","article-title":"Controversies in the use of new bone-modifying therapies in multiple myeloma","volume":"193","author":"Terpos","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41408-017-0015-x","article-title":"Correlation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS)","volume":"7","author":"Lipe","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1080\/10428194.2023.2197537","article-title":"Patterns of target organ amyloid deposition in patients with AL amyloidosis; role for diagnosis and prognosis","volume":"64","author":"Fotiou","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.echo.2010.03.027","article-title":"Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: An observational cohort study","volume":"23","author":"Bellavia","year":"2010","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1038\/s41598-019-44912-x","article-title":"Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure","volume":"9","author":"Tahir","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.19042","article-title":"Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy","volume":"203","author":"Theodorakakou","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/13506129.2018.1540410","article-title":"Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis","volume":"25","author":"Kastritis","year":"2018","journal-title":"Amyloid"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/bloodadvances.2019000147","article-title":"Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone","volume":"3","author":"Kastritis","year":"2019","journal-title":"Blood Adv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ehf2.13701","article-title":"Thromboembolism and bleeding in systemic amyloidosis: A review","volume":"9","author":"Nicol","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/13506129.2020.1798922","article-title":"Arterial thrombo-embolic events in cardiac amyloidosis: A look beyond atrial fibrillation","volume":"28","author":"Cappelli","year":"2021","journal-title":"Amyloid"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2020.1798224","article-title":"Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis","volume":"28","author":"Kastritis","year":"2021","journal-title":"Amyloid"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/hon.3135","article-title":"Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease","volume":"41","author":"Theodorakakou","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/bs.acc.2020.09.006","article-title":"Cryoglobulins: Identification, classification, and novel biomarkers of mysterious proteins","volume":"104","author":"Napodano","year":"2021","journal-title":"Adv. Clin. Chem."},{"key":"ref_66","unstructured":"DynaMed (2023, October 03). Cryoglobulinemia Type I. EBSCO Information Services. Available online: https:\/\/www.dynamed.com\/condition\/cryoglobulinemia-type-i-1."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.24745","article-title":"Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia","volume":"92","author":"Sidana","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"744648","DOI":"10.3389\/fcvm.2021.744648","article-title":"Clinical Characteristics of Cryoglobulinemia with Cardiac Involvement in a Single Center","volume":"8","author":"He","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2016.1.226","article-title":"Cold agglutinin disease","volume":"2016","author":"Berentsen","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/rth2.12333","article-title":"Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis","volume":"4","author":"Broome","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e000579","DOI":"10.1136\/lupus-2021-000579","article-title":"Cardiovascular risk management in antiphospholipid syndrome: Trends over time and comparison with rheumatoid arthritis and diabetes mellitus","volume":"8","author":"Bolla","year":"2021","journal-title":"Lupus Sci. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/jcp.46.7.678","article-title":"Waldenstrom\u2019s macroglobulinaemia secreting a paraprotein with lupus anticoagulant activity: Possible association with gastrointestinal tract disease and malabsorption","volume":"46","author":"Tait","year":"1993","journal-title":"J. Clin. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-012-1600-5","article-title":"Lupus anticoagulant hypoprothrombinemia syndrome in Bence-Jones protein kappa-type multiple myeloma patient with phosphatidylserine-dependent antiprothrombin antibody","volume":"92","author":"Hara","year":"2013","journal-title":"Ann. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00296-002-0206-y","article-title":"A case of Waldenstroem\u2019s disease with a monoclonal IgM antiphospholipid antibody","volume":"22","author":"Scholmerich","year":"2002","journal-title":"Rheumatol. Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/ajcp\/101.4.471","article-title":"Incidence of antiphospholipid antibodies in patients with monoclonal gammopathy of undetermined significance","volume":"101","author":"Stern","year":"1994","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Wu, X.Y., Yin, Y.F., Teng, J.L., Zhang, L.W., and Yang, C.D. (2017). IgMk paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: A case report. BMC Immunol., 18.","DOI":"10.1186\/s12865-017-0213-0"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1055\/a-1366-9379","article-title":"Antiphospholipid Syndrome with Monoclonal Gammopathy-A Mechanism for Recurrent Thrombosis?","volume":"121","author":"Doyle","year":"2021","journal-title":"Thromb. Haemost."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jdcr.2019.01.013","article-title":"Evidence for immunoglobulin-mediated vasculitis caused by monoclonal gammopathy in monoclonal gammopathy of unclear significance prompting oncologic treatment","volume":"5","author":"Drerup","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/1346-8138.14466","article-title":"Leukocytoclastic vasculitis associated with immunoglobulin A lambda monoclonal gammopathy of undetermined significance: A case report and review of previously reported cases","volume":"45","author":"Umemura","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0002-9343(70)80012-2","article-title":"Plasma cell myeloma associated with an unusual myeloma protein causing impairment of fibrin aggregation and platelet function in a patient with multiple malignancy","volume":"48","author":"Cohen","year":"1970","journal-title":"Am. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3816\/CLM.2007.n.027","article-title":"Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders","volume":"7","author":"Auwerda","year":"2007","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11239-014-1140-z","article-title":"Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"39","author":"Crowley","year":"2015","journal-title":"J. Thromb. Thrombolysis"}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/10\/12\/484\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:37:09Z","timestamp":1760132229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/10\/12\/484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":83,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["jcdd10120484"],"URL":"https:\/\/doi.org\/10.3390\/jcdd10120484","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,4]]}}}